*Sponsored by Apimeds Pharmaceuticals US Inc
Hello Everyone,
Yesterday’s profile exploded pretty quick and saw as much as 18% during the session. We have something we feel is right in a zone where it could bounce after recent movement. Pull up APUS. Apimeds Pharmaceuticals is a clinical-stage biotech company dedicated to advancing non-opioid, biologic therapies for pain relief.
Traditional biotech companies often follow a familiar pattern—burning significant amounts of cash, diluting shareholders through repeated funding rounds, and racing toward commercialization. Apimeds is pursuing a different strategy. Through its merger with MindWave, the company has incorporated a digital asset platform designed to generate returns alongside conventional funding sources, with the goal of reducing dilution while continuing to advance its clinical programs.
MindWave’s digital asset model is built on three key components: secure corporate BTC custody solutions that allow institutions to safely hold and manage Bitcoin reserves, AI-driven yield strategies designed to generate returns within controlled risk parameters, and a validator-based ecosystem supported by the $NILA token, which creates additional revenue opportunities beyond basic treasury management. As part of this integration, approximately 1,000 BTC has been allocated into a structured treasury framework focused on preserving capital while producing returns to support ongoing research and development.
This approach allows Apimeds to maintain full independence of its pharmaceutical operations, ensuring that its clinical work remains the primary focus, while the digital asset platform serves as a complementary engine for growth and value creation. The company is supported by a recently completed $100 million PIPE financing, providing the capital needed to advance both its therapeutic pipeline and digital infrastructure.
At the same time, Apimeds is approaching several near-term clinical milestones, including a planned Biologics License Application submission following its confirmatory osteoarthritis trial and the initiation of a Phase 3 study for multiple sclerosis-related pain. Notably, these programs are expected to require less than $12 million in total capital, representing a relatively efficient path compared to typical late-stage biotech development.
The activation of its 1,000 BTC treasury further demonstrates the operational readiness and scalability of the MindWave platform. This strategy is unfolding alongside broader market trends, including increasing demand for non-addictive pain treatments amid the ongoing opioid crisis, growing institutional adoption of Bitcoin as a treasury asset, and currently compressed biotech valuations that may present timely opportunities.
By combining large market opportunities in osteoarthritis and MS pain with capital-efficient development, diversified value creation through digital assets, clearly defined near-term milestones, and strong institutional backing, Apimeds is positioning itself differently from traditional biotech firms. Rather than fitting squarely into either biotech or fintech, the company integrates elements of both. With financing secured, its digital treasury in place, and clinical programs progressing, Apimeds has established a foundation for its next phase of growth.
More than 32 million people in the U.S. live with osteoarthritis, while millions of others suffer from severe pain linked to multiple sclerosis—without any approved treatment options. For years, patients have had to choose between imperfect solutions: NSAIDs that carry cardiovascular risks, corticosteroids with significant side effects, costly biologics with inconsistent outcomes, or opioids that contribute to a widespread addiction crisis claiming tens of thousands of lives each year.
The demand for better options is clear. The U.S. osteoarthritis treatment market alone was valued at $8.28 billion in 2022 and is expected to grow to over $20 billion by 2032.
Apimeds Pharmaceuticals (NYSE: APUS) sits at the crossroads of this urgent medical need and a new model for biotech financing.
After completing its merger with MindWave Innovations Inc. and securing $100 million through a PIPE financing, the company now operates a distinctive dual-platform structure:
Advanced Non-Opioid Pain Therapy Pipeline
Apitox, derived from honeybee venom, introduces a new approach to targeting inflammation and immune responses—offering potential where traditional treatments have fallen short.
AI-Powered Digital Asset Treasury
MindWave contributes an institutional-grade digital asset platform combining secure BTC treasury management, AI-driven yield strategies, and a validator-based ecosystem supported by the $NILA token.
Clinical Opportunity
Efficient Pathway to Commercialization
Apitox for Knee Osteoarthritis
Apimeds already holds Phase 3 data for Apitox in knee osteoarthritis, one of the most widespread and underserved pain conditions. A confirmatory study is expected to cost under $10 million—significantly less than typical late-stage biotech programs.
If successful, the company plans to submit a Biologics License Application (BLA) to the FDA, marking the final regulatory step before entering a market approaching $20 billion.
Apitox for MS-Related Pain
An even more compelling opportunity lies in multiple sclerosis pain, where no FDA-approved therapies currently exist.
Apimeds holds rights to an FDA-cleared Investigational New Drug (IND) application for a Phase 3 trial. The study design is simple: a single-site trial involving 25–35 patients to confirm pain reduction during MS flare-ups. Early anecdotal evidence is encouraging, and the study is expected to cost under $2 million.
This represents a true “blue ocean” opportunity—an unmet need with no direct competition and a defined regulatory path.
What Sets Apitox Apart
Compared to traditional treatments, Apitox offers:
- A unique mechanism based on the therapeutic properties of honeybee venom
- An option for patients who haven’t responded well to existing therapies
- Access to a largely untapped space in inflammation and immune modulation
- A foundation rooted in toxin-based therapies, which have a track record of success
Rather than being just another pain medication, Apitox aims to fill a critical gap in treating complex, chronic conditions.
NEWS
1 day ago
Mar 25, 2026
Mar 24, 2026
Feb 11, 2026
Dec 17, 2025
Dec 10, 2025
Dec 1, 2025
Nov 10, 2025
Oct 14, 2025
Sep 15, 2025
Dec 1, 2025
Nov 10, 2025
Oct 14, 2025
Sep 15, 2025
MANAGEMENT
Dr. Vin Menon
Chief Executive Officer and Director
Dr. Vin Menon is a veteran in the technology services industry, who can be credited with the strategic direction behind several disruptive technology companies. In the corporate world, he has held various leadership positions at multinational corporations like HP & Compaq with global responsibilities. Driven by his passion for technology and innovation, Dr. Menon has been a forerunner in technological innovation and has helped create the business ecosystem of disruptive technologies and high-growth companies. His experience has helped him in the technology space as an entrepreneur and advisor, leading several startups from inception to meteoric growth across continents. Dr. Menon’s proven track record of setting up motivated and high caliber teams in the technology and services industry, establishing development centers from scratch to scale, and building company competencies led him to being awarded ‘Entrepreneur of the Year 2012’ by Rotary-ASME, ‘Outstanding Entrepreneur Award 2011’ by APEA, the ‘Spirit of Enterprise 2010’ by SOE Singapore. Dr. Menon was also selected as a ‘Leading Indian Entrepreneur of the Year 2010’ by the Singapore Indian Chamber of Commerce.
From the years 2021 to 2023 he co- founded and served as Strategic Advisor to CGCX, a Fintech, decentralized finance, and digital assets platform, where he provided strategic advisory services and growth initiatives. He currently serves as Chief Executive Officer of AQUAE Impact (AQUAE Impact Exchange Co. L.L.C / AQUAE Impact), a sustainable financial and environmental assets platform that uses blockchain technology and artificial intelligence, which he co-founded and currently forms part of its executive leadership providing oversight of product and sustainability initiatives. He also currently serves as Chief Executive Officer of AQUAE Labs Pte Ltd, which is the research and development and technology arm of AQUAE Impact, where he provides product and technology leadership, measurement, reporting, and verification of environmental credits. Additionally, he currently occupies the role of Strategic Advisor of TechyTrade FZ-LLC, which is a bitcoin-backed company that operates in the digital asset and treasury innovation space. Dr. Menon is also a champion of techno-preneurship and was serving on the Board of Directors of the Spirit of Enterprise (SOE) and the Mentoring Programme under Action Community for Entrepreneurship (ACE) by SPRING Singapore. Moreover, he completed his bachelor’s degree in computer applications from India, with first-class honors. He has also completed the following programs: Advanced Management Program (AMP) at NTU-Berkeley (Haas Business School, California) and Advanced Management Program (AMP) at The Wharton School (University of Pennsylvania, USA) specialized in Finance. Dr. Menon obtained an EMBA from the Nanyang Technological University (NTU) in Singapore. Lastly, he completed his PhD, Blockchain for Impact in Healthcare from The Open International University for Complementary Medicine in collaboration with Al-Farabi Kazakh National University, Kazakhstan 2019.
We believe that these experiences provide Dr. Menon with the skills necessary to lead the Company as its Chief Executive officer and members of the board, including overseeing the Company’s strategy, operations, financial performance, and overall corporate governance.
Sungjoon Chae
Co-Chief Executive Officer
Sungjoon Chae was named co-CEO in May 2026. He is a Strategic Principal Architect and Urban Designer with a distinguished background in leading large-scale architectural and planning initiatives. Leveraging a Master of Architecture in Urban Design from Harvard University, he possesses deep expertise in urban revitalization and spatial planning. He is recognized for steering cross-functional teams and delivering design excellence in competitive markets.
Erick J. Frim
Chief Financial Officer
Mr. Frim has over 40 years of experience as an accountant, financial executive and consultant. He joined Helio Corporation in December 2024. In 2019, he joined CFO Squad and as a partner in the CFO Squad, LLC Mr. Frim advised clients on technical accounting and regulatory compliance, assisting numerous companies with their initial public offerings. Prior to the CFO Squad, Mr. Frim served as a director in the public company audit practice of EisnerAmper LLP. Mr. Frim as also served as a financial executive for digital media pioneer DIVA Systems Corporation. A former CPA, he has a BS in Accounting from Ball State University.
Dr. Christopher Kim, MD
Chief Medical Officer
Dr. Christopher Kim has been our Chief Medical Officer since our inception and served as our interim Chief Executive Officer from July 2022 to September 2023.
Dr. Kim is the inventor and developer of Apitox and the founder of Apimeds Korea, where he has served as a director since its inception. Mr. Kim served as the Chief Executive Officer of Apimeds Korea from May 2003 to August 2011. Prior to founding Apimeds Korea, Dr. Kim lead with the support of Guju Pharmaceuticals, clinical trials for Apitoxin in Korea, which was approved by the Korea Food and Drug Administration in 2003 for relief of pain and inflammation for patients with Osteoarthritis. In 2005, he began focusing on the clinical development of Apitox in the United States, including the first of two-Phase III clinical studies for Osteoarthritis. Prior to his time with Apimeds Korea, Dr. Kim served as the President of the International Pain Institute of New Jersey from January 1983 to May 2003, a center for chronic pain and other disabling diseases that conducted clinical research and provided treatment. He served as a professor at Biomedical Center, CHA Graduate School of Medicine in Korea from March 2005 to February 2017.
Dr. Kim is a licensed physician in New Jersey, New York and Korea and a Pain Medicine Specialist (American Board). Over the past twenty years, Dr. Kim has treated thousands of chronically disabled patients with autoimmune diseases, including MS. Dr. Kim received his medical degree from the School of Medicine, CN University in Korea.
Susan Kramer, DrPH
Senior Vice President, Development
Susan Kramer has more than 30 years’ experience in biopharmaceutical research and development, with the first 18 at Genentech. She was a co-founder of Corthera, Inc., subsequently acquired by Novartis, and has held senior management and key alliance management roles at a number of biotech companies, including XOMA, Anesiva and Annexon Biosciences. She most recently served as Executive Vice President of Development at Concentric Analgesics. She has led development teams for both protein and small molecule therapeutics in the US and globally.
Dr. Kramer received a BA from College of St. Scholastica, an MA in Education from Central Michigan University and earned her MPH and DrPH in Biomedical Sciences (Virology) from the University of California Berkeley. She has served on numerous science and education boards and committees.
Brian Peters
Senior Vice President, ai² Division
Brian Peters is a senior commercial executive with over 30 years of experience in global branding, business development, and product launches across neurology, rheumatology, hematology, cardiology and rare diseases. Most recently, he served as Chief Strategy & Insights Officer at Heller Agency, leading strategic planning, business development, and market positioning. Prior to that, he spent over a decade at Medexus Pharma, where he oversaw U.S. marketing and sales efforts, launched multiple products, and led a high-performing sales and marketing team that drove significant market share growth. He played an instrumental role in the acquisitions of IXINITY, Grafapex, and Gleolan, expanding Medexus’ U.S. portfolio.
Mr. Peters has held senior marketing and commercial leadership roles at Chiesi USA, Accera, Gilead Sciences, Biovail Pharmaceuticals, and G.D. Searle, playing a pivotal role in product commercialization, marketing strategy, and sales leadership.
He serves on the Future Pharma and PM360 Editorial Advisory Boards and is a frequent speaker at pharmaceutical conferences. Mr. Peters holds a B.A. in Communications from Indiana University Bloomington and is currently a board member of the non-profit organization Cardz for Kidz.
SINCERELY,
DISCLAIMER
MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.
The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell. The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.
Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.
The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.
The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.
The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.
The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk. The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.
Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com to obtain information about the Issuers.
Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com and www.sec.gov.
The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:
▪ An independent advisor or consultant;
▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;
▪ Stock picker;
▪ Securities trading expert;
▪ Securities researcher or analyst;
▪ Financial planner or financial planning;
▪ Provider of stock recommendations;
▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or
▪ Making an offer or sale of securities or solicitation to purchase securities.
An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information. Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.
▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.
▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.
▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.
▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.
▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.
▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org. You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.
▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.
The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:
Name of Issuer: 3rd party on behalf of Apimeds Pharmaceuticals US Inc
Amount of Cash Compensation: twenty five thousand usd
Period of Publication of Information: One day campaign beginning and ending on May seventh twenty twenty six
Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.
By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.